Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2019-09-26 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-09-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-25 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-18 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the completion of a convertible note offering, details of the indenture and notes, capped call transactions, and related financial obligations. It includes descriptions of the terms of the notes, use of proceeds, and related agreements. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document is not a full financial report but an announcement of a financing event and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing transaction, supporting a high confidence in this classification.
2019-09-16 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a private offering of convertible senior notes, including pricing, expected proceeds, and related financial transactions. It is not a full financial report but an update on a capital raising event. The document includes a press release as an exhibit announcing the offering. Given the focus on financing activities and capital structure changes, this fits the category of Capital/Financing Update (CAP). The document length and detail support this classification rather than a brief announcement or a full annual/interim report.
2019-09-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses a planned offering of convertible senior notes and related capped call transactions, which are financing activities. There are no detailed financial statements or comprehensive financial analysis present, just an announcement of a financing event. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is not a brief announcement or a report publication notice. Hence, the classification is CAP with high confidence.
2019-09-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.